Total Payments
$72,155
2024 Payments
$7,630
Companies
21
Transactions
262
Medicare Patients
2,772
Medicare Billing
$550,658
Payment Breakdown by Category
Other$66,108 (91.6%)
Food & Beverage$3,883 (5.4%)
Travel$2,164 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,108 | 40 | 91.6% |
| Food and Beverage | $3,883 | 203 | 5.4% |
| Travel and Lodging | $2,164 | 19 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $66,535 | 142 | $0 (2024) |
| Allergan, Inc. | $3,168 | 15 | $0 (2022) |
| Collegium Pharmaceutical, Inc. | $714.68 | 42 | $0 (2022) |
| SK Life Science, Inc. | $437.20 | 1 | $0 (2022) |
| Scilex Pharmaceuticals Inc. | $234.67 | 12 | $0 (2022) |
| Novo Nordisk Inc | $146.10 | 3 | $0 (2022) |
| Merz Pharmaceuticals, LLC | $134.64 | 5 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $108.52 | 1 | $0 (2022) |
| Horizon Therapeutics plc | $94.73 | 6 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.35 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,630 | 9 | ABBVIE INC. ($7,630) |
| 2023 | $3,924 | 8 | ABBVIE INC. ($3,924) |
| 2022 | $27,133 | 106 | ABBVIE INC. ($25,854) |
| 2021 | $33,468 | 139 | AbbVie Inc. ($29,128) |
All Payment Transactions
262 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/09/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/02/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $80.16 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $28.60 | General |
| Category: NEUROSCIENCE | ||||||
| 03/26/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,345.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2024 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $110.55 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/06/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: NEUROSCIENCE | ||||||
| 11/30/2023 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/07/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $251.25 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/18/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: NEUROSCIENCE | ||||||
| 04/17/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $251.25 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/30/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2022 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Neuromodulation | ||||||
| 11/23/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: Gastroenterology | ||||||
| 11/17/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $1.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2022 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,345.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2022 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $85.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 183 | 321 | $223,185 | $20,569 |
| 2022 | 12 | 632 | 9,842 | $306,727 | $128,815 |
| 2021 | 11 | 955 | 13,884 | $450,810 | $211,971 |
| 2020 | 12 | 1,002 | 12,890 | $409,034 | $189,303 |
Total Patients
2,772
Total Services
36,937
Medicare Billing
$550,658
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 66 | 151 | $88,152 | $7,718 | 8.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 99 | $74,781 | $7,612 | 10.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 70 | 71 | $60,252 | $5,239 | 8.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 13 | 6,500 | $61,100 | $31,706 | 51.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 214 | 616 | $83,160 | $30,240 | 36.4% |
| J7322 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 2022 | 17 | 1,440 | $50,400 | $29,596 | 58.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 138 | 286 | $57,200 | $20,588 | 36.0% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 46 | 109 | $18,150 | $7,175 | 39.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 13 | 33 | $7,755 | $3,252 | 41.9% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2022 | 28 | 62 | $9,610 | $2,212 | 23.0% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2022 | 15 | 38 | $6,400 | $1,769 | 27.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $2,860 | $1,194 | 41.8% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 11 | 12 | $1,260 | $542.28 | 43.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 60 | 594 | $1,782 | $518.03 | 29.1% |
| J3490 | Unclassified drugs | Office | 2022 | 66 | 141 | $7,050 | $23.82 | 0.3% |
| J7322 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 2021 | 28 | 2,352 | $82,320 | $59,245 | 72.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 281 | 673 | $130,300 | $51,874 | 39.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 16 | 8,890 | $83,566 | $42,962 | 51.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 264 | 629 | $81,330 | $34,297 | 42.2% |
| 20611 | Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance | Office | 2021 | 66 | 171 | $27,900 | $11,509 | 41.3% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 18 | 48 | $11,280 | $4,824 | 42.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 59 | 72 | $5,760 | $2,543 | 44.1% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Office | 2021 | 36 | 60 | $9,300 | $2,140 | 23.0% |
| 64450 | Injection of anesthetic agent and/or steroid into other peripheral nerve or branch | Office | 2021 | 23 | 39 | $6,240 | $1,836 | 29.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 79 | 738 | $2,214 | $714.87 | 32.3% |
About Peter Kalogerinis, PA-C
Peter Kalogerinis, PA-C is a Physician Assistant healthcare provider based in Fayetteville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2011. The National Provider Identifier (NPI) number assigned to this provider is 1740584853.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Peter Kalogerinis, PA-C has received a total of $72,155 in payments from pharmaceutical and medical device companies, with $7,630 received in 2024. These payments were reported across 262 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($66,108).
As a Medicare-enrolled provider, Kalogerinis has provided services to 2,772 Medicare beneficiaries, totaling 36,937 services with total Medicare billing of $550,658. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Fayetteville, NC
- Active Since 01/04/2011
- Last Updated 09/03/2025
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1740584853
Products in Payments
- UBRELVY (Drug) $57,441
- QULIPTA (Drug) $12,034
- XTAMPZA (Drug) $673.43
- XCOPRI (Drug) $437.20
- BOTOX (Biological) $210.48
- ZTLido (Drug) $171.68
- Xeomin (Biological) $134.64
- Wegovy (Drug) $133.19
- NURTEC ODT (Drug) $119.66
- ACTHAR (Biological) $108.52
- RELISTOR (Drug) $88.35
- PENNSAID (Drug) $77.58
- BELBUCA (Drug) $61.53
- Proclaim IPG (Device) $59.10
- Nuedexta (Drug) $52.28
- Licart (Drug) $45.28
- ELYXYB - celecoxib (Drug) $41.25
- HYMOVIS (Device) $39.81
- PROCLAIM (Device) $23.12
- ZENPEP (Drug) $17.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Fayetteville
William Davis
Physician Assistant — Payments: $9,192
Physician Assistant $9,192
Mr. William Cotton, Pa-C, PA-C
Physician Assistant — Payments: $6,861
Physician Assistant $6,861
Emily Townsend, Pa-C, PA-C
Physician Assistant — Payments: $6,735
Physician Assistant $6,735
Thomas Daignault, Pa, PA
Physician Assistant — Payments: $5,954
Physician Assistant $5,954
Daniel Green
Physician Assistant — Payments: $5,626
Physician Assistant $5,626
Mr. Joshua Matthews, Pa-C, PA-C
Physician Assistant — Payments: $5,342
Physician Assistant $5,342